Gigxone-TZ 250 Injection is a sterile, injectable formulation combining Ceftriaxone 250 mg, a third-generation cephalosporin antibiotic, with Tazobactam 31.25 mg, a potent β-lactamase inhibitor. This combination enhances the antibacterial spectrum by inhibiting β-lactamase enzymes produced by resistant bacteria, thereby restoring the efficacy of Ceftriaxone against β-lactamase-producing pathogens. Gigxone-TZ 250 is indicated for the treatment of a wide range of bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and septicemia caused by susceptible organisms. The drug exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including strains resistant to other β-lactam antibiotics. Administration is via intramuscular or intravenous injection, with dosage adjusted according to the severity of infection and renal function status. Careful monitoring is advised in patients with hypersensitivity to β-lactams, hepatic or renal impairment. Common adverse effects may include local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions. Gigxone-TZ 250 Injection should be used under strict medical supervision with appropriate microbiological guidance to minimize the development of resistance and ensure optimal therapeutic outcomes.